US 12,440,492 B2
Pharmaceutical compositions comprising AKT protein kinase inhibitors
Reinhard Reents, Basel (CH); Pirmin Hidber, Basel (CH); Andre Hell, Basel (CH); Peter Steidle, Basel (CH); Martin Wunderlich, Basel (CH); Marie Pepelnjak, Basel (CH); Francis Gosselin, South San Francisco, CA (US); and Edward Yost, South San Francisco, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Mar. 14, 2024, as Appl. No. 18/605,258.
Application 17/724,045 is a division of application No. 15/672,505, filed on Aug. 9, 2017, granted, now 11,337,977, issued on May 24, 2022.
Application 18/605,258 is a continuation of application No. 17/724,045, filed on Apr. 19, 2022, granted, now 11,969,426.
Claims priority of provisional application 62/373,252, filed on Aug. 10, 2016.
Prior Publication US 2025/0009749 A1, Jan. 9, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/517 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01)
CPC A61K 31/517 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2077 (2013.01); A61K 9/2095 (2013.01); A61K 9/28 (2013.01); A61K 9/284 (2013.01)] 17 Claims
 
1. A pharmaceutical composition comprising:
(a) 20-40% wt ipatasertib or a pharmaceutically acceptable salt thereof,
(b) 20-65% wt microcrystalline cellulose,
(c) 0-50% wt pregelatinized starch,
(d) 0-10% wt colloidal silica,
(e) 1-10% wt polyvinylpyrrolidone,
(f) 0-5% wt colloidal silica,
(g) 3-10% wt croscarmellose sodium, and
(h) 0-5% wt magnesium stearate.